riluzole has been researched along with Acute Relapsing Multiple Sclerosis in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fatigue is a common and disabling symptom of multiple sclerosis (MS) patients." | 1.43 | Longitudinal associations between brain structural changes and fatigue in early MS. ( Azevedo, C; Maghzi, AH; Nourbakhsh, B; Nunan-Saah, J; Pelletier, D; Spain, R; Waubant, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hollingworth, S | 1 |
| Walker, K | 1 |
| Page, A | 1 |
| Eadie, M | 1 |
| Nourbakhsh, B | 3 |
| Azevedo, C | 2 |
| Nunan-Saah, J | 1 |
| Maghzi, AH | 2 |
| Spain, R | 2 |
| Pelletier, D | 3 |
| Waubant, E | 3 |
| Kuhle, J | 1 |
| Grant, D | 1 |
| Morant, S | 1 |
| Barro, C | 1 |
| Yaldizli, Ö | 1 |
| Giovannoni, G | 1 |
| Gnanapavan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis[NCT00501943] | Phase 2 | 43 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis.[NCT04593082] | 116 participants (Anticipated) | Observational | 2021-06-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline MSFC data is compared to MSFC data collected during the timepoints. The MSFC is a three-part, standardized, quantitative, assessment instrument that measures the clinical dimensions of leg function, arm/hand function and cognitive function and the components include Timed 25-Foot walk, 9-Hole Peg Test and Paced Auditory Serial Addition Test. (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.041 |
| Placebo | 0.052 |
The baseline data of grey matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -14.369 |
| Placebo | -18.444 |
The baseline data of white matter volume obtained from the MRI images is compared to data obtained at time points using SIENA (Structural Image Evaluation using Normalization of Atrophy) and SIENAX (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -1.75 |
| Placebo | -9.69 |
Baseline RNFL data is compared to the RNFL data collected during the timepoint, and the changes in RNFL is measured using optical coherence tomography (OCT). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -4.670 |
| Placebo | -1.839 |
Baseline SDMT data were compared to SDMT data collected during the timepoints. A simple substitution task, the SDMT gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The total score is the total number of correctly completed boxes in the time allowed. The test score range is from 0(worst outcome) to 110 (best outcome). (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | 0.342 |
| Placebo | 0.417 |
Baseline MRI is compared to MRI images collected during subsequent timepoints. The percent brain volume change is measured using SIENAX (Structural Image Evaluation using Normalization of Atrophy-X) (NCT00501943)
Timeframe: Baseline, Month-3, Month-6, Month-12, Month-18 and Month-24
| Intervention | percent change per year (Mean) |
|---|---|
| Riluzole | -0.862 |
| Placebo | -0.49 |
2 trials available for riluzole and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Brain; Cross-Sectional Studies; Disability Evaluation; Disea | 2016 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
Topics: Adjuvants, Immunologic; Adult; Atrophy; Biomarkers; Brain; Disability Evaluation; Disease Progressio | 2017 |
2 other studies available for riluzole and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geograph | 2013 |
Longitudinal associations between brain structural changes and fatigue in early MS.
Topics: Adult; Atrophy; Brain; Fatigue; Female; Humans; Longitudinal Studies; Magnetic Resonance Imaging; Ma | 2016 |